Jeremy Stephen Parker

Jeremy Stephen Parker

Auto-generated profile, based on publicly available information

Jeremy Stephen Parker

Early Chemical Development, Pharmaceutical Development, R&D, AstraZeneca, Macclesfield, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2019 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
JBJonathan D. Bargh
Jonathan D. Bargh
AIAlbert Isidro-Llobet
Albert Isidro-Llobet
JPJeremy S. Parker
Jeremy S. Parker
DSDavid Spring
David Spring
This tutorial review summarises the advances in the field of cleavable linker technologies for antibody–drug conjugates (ADCs).

8 December 2020 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
SWStephen J. Walsh
Stephen J. Walsh
JBJonathan D. Bargh
Jonathan D. Bargh
FDFriederike M. Dannheim
Friederike M. Dannheim
AHAbigail R. Hanby
Abigail R. Hanby
HSHikaru Seki
Hikaru Seki
DSDavid Spring
David Spring
Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. This review summarises the advances made in the construction of homogenous ADCs.

9 November 2018 in Chemical Science
Verified
Journal Article
Open access
PDF file
SWStephen J. Walsh
Stephen J. Walsh
SOSoleilmane Omarjee
Soleilmane Omarjee
WGWarren R. J. D. Galloway
Warren R. J. D. Galloway
TKTerence T.-L. Kwan
Terence T.-L. Kwan
HSHannah F. Sore
Hannah F. Sore
DSDavid Spring
David Spring
Antibody–drug conjugates (ADCs) are a class of targeted therapeutics that utilize the specificity of antibodies to selectively deliver highly potent cytotoxins to target cells. Although recent years have witnessed significant interest in ADCs, problems remain with the standard linkage chemistries used for cytotoxin-antibody bioconjugation. These typically (1) generate unstable constructs, which may lead to premature cytotoxin release, (2) often give a wide variance in drug–antibody ratios (DAR) and (3) have poor control of attachment location on the antibody, resulting in a variable pharmacokinetic profile. Herein, we report a novel divinylpyrimidine (DVP) linker platform for selective bioconjugation via covalent re-bridging of reduced disulfide bonds on native antibodies. Model studies using the non-engineered trastuzumab antibody validate the utility of this linker platform for the generic generation of highly plasma-stable and functional antibody constructs that incorporate variable biologically relevant payloads (including cytotoxins) in an efficient and site-selective manner with precise control over DAR. DVP linkers were also used to efficiently re-bridge both monomeric and dimeric protein systems, demonstrating their potential utility for general protein modification, protein stabilisation or the development of other protein-conjugate therapeutics.

25 January 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
CPClaire M. Patterson
Claire M. Patterson
SBSrividya B. Balachander
Srividya B. Balachander
IGIain Grant
Iain Grant
PPPetar Pop-Damkov
Petar Pop-Damkov
BKBrian Kelly
Brian Kelly
MAMarianne B. Ashford
Marianne B. Ashford
Dual Bcl-2/Bcl-xL inhibitors are expected to deliver therapeutic benefit in many haematological and solid malignancies, however, their use is limited by tolerability issues. AZD4320, a potent dual Bcl-2/Bcl-xL inhibitor, has shown good efficacy however had dose limiting cardiovascular toxicity in preclinical species, coupled with challenging physicochemical properties, which prevented its clinical development. Here, we describe the design and development of AZD0466, a drug-dendrimer conjugate, where AZD4320 is chemically conjugated to a PEGylated poly-lysine dendrimer. Mathematical modelling was employed to determine the optimal release rate of the drug from the dendrimer for maximal therapeutic index in terms of preclinical anti-tumour efficacy and cardiovascular tolerability. The optimised candidate is shown to be efficacious and better tolerated in preclinical models compared with AZD4320 alone. The AZD4320-dendrimer conjugate (AZD0466) identified, through mathematical modelling, has resulted in an improved therapeutic index and thus enabled progression of this promising dual Bcl-2/Bcl-xL inhibitor into clinical development.

16 July 2020 in Biomacromolecules
Verified
Journal Article
Closed access
RERichard M. England
Richard M. England
JMJennifer I. Moss
Jennifer I. Moss
AGAnders Gunnarsson
Anders Gunnarsson
JPJeremy Stephen Parker
Jeremy Stephen Parker
MAMarianne B. Ashford
Marianne B. Ashford
JHJennifer Hare
Jennifer Hare

7 June 2021 in Chemical Science
Verified
Journal Article
Open access
PDF file
HSHikaru Seki
Hikaru Seki
SWStephen J. Walsh
Stephen J. Walsh
JBJonathan D. Bargh
Jonathan D. Bargh
JPJeremy S. Parker
Jeremy S. Parker
JCJason Carroll
Jason Carroll
DSDavid Spring
David Spring
Vinylheteroarene linkers can chemoselectively modify cysteine residues in proteins and antibodies. These linkers give stable bioconjugates, and were used to synthesise efficacious antibody-drug conjugates.